The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Halo 110-101: Early safety results of pegvorhyaluronidase alfa (PEGPH20; PVHA) + cisplatin (C) + gemcitabine (G) ± atezolizumab (ATZ) in patients (pts) with locally advanced or metastatic cholangiocarcinoma (CCA) and gallbladder cancer (GBC).
 
Do-Youn Oh
Research Funding - AstraZeneca
 
Mann Muhsin
Employment - Halozyme
Stock and Other Ownership Interests - Halozyme
Research Funding - Halozyme
Travel, Accommodations, Expenses - Halozyme
 
Andrea J. Bullock
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Medtronic
Consulting or Advisory Role - Bayer; Celgene; Exelixis; Halozyme; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Halozyme
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - 3DMedcare; Agios; Alignmed; Amgen; Antengene; Aptus Clinical; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BiolineRx (I); Boston Scientific; BridgeBio Pharma; Bristol-Myers Squibb; CARsgen Therapeutics; CASI Pharmaceuticals; Celgene; Celsion; Cipla; CytomX Therapeutics (I); Daiichi Sankyo; Debiopharm Group; Delcath Systems; Eisai; EMD Serono (I); Exelixis; Genoscience Pharma; Gilead Sciences (I); Halozyme; Halozyme; Hengrui Pharmaceutical; Inovio Pharmaceuticals; Ipsen; Janssen (I); Jazz Pharmaceuticals; Kyowa Hakko Kirin; LAM Therapeutics; Lilly; Loxo (I); Medimmune; Merck Serono; Minapharma; Newlink Genetics (I); Novella Clinical; Onxeo; PCI Biotech; PCI Biotech; Pfizer (I); Pharmacyclics (I); Pharmacyte Biotech (I); Pieris Pharmaceuticals (I); QED Therapeutics; RedHill Biopharma; Roche; Sanofi; SERVIER; Silenseed (I); Sillajen; Sirtex Medical; Sirtex Medical; SOBI (I); Targovax (I); Tekmira; Tekmira; twoXAR; Vicus Therapeutics (I); Yakult Pharmaceutical; Yakult Pharmaceutical; Yiviva
Research Funding - Acta Biologica (Inst); Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); Novartis (Inst); OncoMed (Inst); OncoQuest (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris
 
Rachna T. Shroff
Consulting or Advisory Role - Halozyme; Seagen
Research Funding - Agios; Celgene; Halozyme; Lilly
Travel, Accommodations, Expenses - Halozyme; Seagen
 
Darren Sigal
Stock and Other Ownership Interests - Bristol-Myers Squibb; Halozyme; Novartis
Speakers' Bureau - Bayer; Celgene
Research Funding - Halozyme (Inst)
 
Vincent Chung
Consulting or Advisory Role - Celgene; Five Prime Therapeutics; Ipsen; Perthera
Speakers' Bureau - Celgene
 
J. Randolph Hecht
Honoraria - Aduro Biotech; Amgen; ARMO BioSciences; Astellas Oncology; Bristol-Myers Squibb; Gritstone Bio; Halozyme; Roche
Consulting or Advisory Role - Aduro Biotech; Amgen; ARMO BioSciences; Astellas Oncology; Bristol-Myers Squibb; Gritstone Bio; Halozyme; Roche
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); Forty Seven (Inst); Halozyme (Inst); Merck (Inst); Merrimack (Inst)
Travel, Accommodations, Expenses - Amgen; ARMO BioSciences; Bristol-Myers Squibb
 
Wilson Wu
Employment - Halozyme
Stock and Other Ownership Interests - Halozyme
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; GlaxoSmithKline
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); Fujifilm (Inst); G1 Therapeutics; Halozyme (Inst); Inspyr Therapeutics; Insys Therapeutics (Inst); Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TD2
Research Funding - Agios (Inst); ARIAD (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene